ICRF-159: current status and clinical prospects.
D000505:Alopecia / Q000139:chemically induced; D000818:Animals; D003110:Colonic Neoplasms / Q000188:drug therapy; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D009325:Nausea / Q000139:chemically induced; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use*; D011929:Razoxane / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy
D010879:Piperazines; D011929:Razoxane